Sorry, I misunderstood your prior posts. I'd been talking about yahoo's calendar, and I thought you were stating that Curis has been reporting a week following yahoo's calendar date, which I noted was initially this prior Monday. Yahoo's calendar date obviously means nothing. Well, hopefully they announce soon, at any rate.
25k is a token gesture does not show conviction. And Roche just wasted a whole year, after early approval and may be a record breaking launch, now they tell us they don't even know where the patients are. The numbers so far tell us they are not even hitting the Gorlin patients hard.
Exactly why do we think CHMP will send this thru the roof when the stock is so weak and Roche is barely selling the product? It might get back to 3.50, may be and CHMP is not guaranteed, we might be repeating this conversation in March. I don't know TA but have you at least seen the chart, do you think there is support here, if so how strong is it? I promised myself this the year I stop behaving like retail investor altogether. Wall St wants to crush u and I, how is else do you explain what has happened to this stock. They were looking at things beyond what we see.
How often do new drugs start off with strong sales? Initial sales mean very little in comparison to investors in comparison to what is forward looking. Estimate of 4th quarter sales based on Roche's annual earnings report (as done by hamster last week) indicate that sales of Erivedge went up by about a third in the fourth quarter from the previous quarter. That is a solid gain, I don't know how much you'd expect sales to gain from quarter to quarter. At this point I feel we are just waiting for Curis' official report to make this point official.
I figure that approval l in Europe would add at least 33% to future sales. That should therefore, at least theoretically, add about the same amount to the stock price. So it should at least, conservatively, approach the $4.00 mark following that occurrence.